Danaher Corporation · NYSE:DHR
Danaher — J.P. Morgan Healthcare Conference 2016
15 slides from Danaher's conference presentation, Jan 12, 2016
Slide 1: J.P. Morgan Healthcare Conference
J.P. MORGAN HEALTHCARE CONFERENCE January 12, 2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities laws. Th
Slide 3: Agenda
Agenda Portfolio Overview Evolution of SCIEX with Danaher The Pall Opportunity
Slide 4: Danaher Today
Danaher Today Outstanding portfolio of businesses Dental Life Sciences & Diagnostics Test & Measurement Industrial Technologies Environmental Water Quality $2.0B Gilbarco Veeder-Root $1.6B Instruments $2.1B Dental $2.7B Product ID $1.6B Automation $0.8B Diagnostics $4.9B Life Sciences $2.4B Matco/He
Slide 5: Secular Growth Drivers
Secular Growth Drivers Revenue Gross Margin Operating Margin Free Cash Flow Post-Separation Danaher Strong growth, free cash flow and earnings profile ROW 6% NA 42% EU 23% HGM 29% Diagnostics 30% Life Sciences 15% Product ID 10% Dental 16% Water Quality 12% Pall Ind 8% Pall LS 9% Business Geography
Slide 6: Danaher's Opportunity
Danaher’s Opportunity United by resilient business models with significant room to improve through DBS Revenue Recurring Revenue* Diagnostics $4.9B 80% Pall $2.8B 75% Dental $2.7B 60% Life Sciences $2.4B 50% Water Quality $2.0B 55% Product ID $1.6B 40% Danaher $16.5B 60% >20% Mid-teens ~1/2 of total
Slide 7: DBS is Our Culture
DBS is Our Culture INNOVATION DEFINES OUR FUTURE DANAHER THE BEST TEAM WINS DANAHER KAIZEN IS OUR CUSTOMERS CUSTOMERS TALK, E LIST! WE COMPETE FOR PERFOR SHAREHOLDERS
Slide 8: SCIEX Overview
SCIEX Overview Well-positioned global leader in mass spectrometry and related LS applications All figures on this slide based on 2015E. Environmental, healthcare and food safety regulations Evolution of life science research HGMs investing in basic and applied research capacity Revenue Breakdown Geo
Slide 9: SCIEX Pre-Acquisition
SCIEX Pre-Acquisition Tremendous opportunity for improvement with DBS *Acquisition closed on January 30, 2010 Suboptimal “virtual JV” structure led to lack of focus Commercial, Operations, R&D separated along JV lines Cadence of innovation was poor No meaningful product launches between 2005 and lat
Slide 10: Years in at SCIEX
5 Years in at SCIEX Similar playbook for success applied at Beckman Coulter, and now Pall Replaced JV structure with customer focused model and improved processes with DBS Significant infusion of DHR talent Targeted investments in innovation driving above-market growth Completely refreshed product p
Slide 11: Pall Overview
Pall Overview 2015* Financials Revenue ~$2.8B OP Margin Mid-teens Revenue Breakdown Outstanding, highly strategic asset with very attractive business model * FYE July 31, 2015 Geographic Mix 29% 31% 38% 75% 25% BioPharma 2015* Revenue: ~$1.0B Medical 2015* Revenue: ~$0.2B Food & Beverage 2015* Reven
Slide 12: The Biopharma Opportunity
The Biopharma Opportunity $4B+ addressable market growing LDD; Pall touches every step of process Core growth market is biologic-based therapies 7 of 10 top-selling drugs are biologics >900 biologic drugs in the approval pipeline Impact from genomics revolution yet to come Attractive market with >80
Slide 13: Focus on Accelerating Growth and Improving Profitability
Focus on Accelerating Growth and Improving Profitability DBS a catalyst for growth acceleration, cost structure improvement Outstanding leadership – a combination of Pall and DHR talent 12 senior leaders plus >50 associates from DHR assisting with DBS adoption and training >90% Pall level 2/3 leader
Slide 14: Summary
Summary Post-separation Danaher well-positioned to drive future earnings outperformance Significant improvement at SCIEX 5 years post acquisition, driven by DBS DBS will help lead the way at Pall, sharpening focus on profitability and accelerating growth
Slide 15: Danaher
DANAHER